Pan et al. found that increased IL-38 could not only inhibit the expression of IL-23R and IL-17A in PBMCs but also suppress inflammation in orbital fibroblasts in TAO patients, and IL-38 could be a potential therapeutic approach for TAO [129]. This evidence concerns the gene IL17A and thromboangiitis obliterans.